Get the Stockscreener App
0.16
54.29%
-0.19
After Hours:
.15
-0.01
-6.25%
Molecular Templates Inc stock is traded at $0.16, with a volume of 8.41M.
It is down -54.29% in the last 24 hours and down -58.76% over the past month.
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.
See More
Previous Close:
$0.35
Open:
$0.15
24h Volume:
8.41M
Relative Volume:
0.60
Market Cap:
$1.05M
Revenue:
$23.48M
Net Income/Loss:
$-15.63M
P/E Ratio:
-0.0129
EPS:
-12.45
Net Cash Flow:
$-23.92M
1W Performance:
-60.00%
1M Performance:
-58.76%
6M Performance:
-86.55%
1Y Performance:
-95.79%
1-Day Range:
$0.135
$0.1849
1-Week Range:
$0.135
$0.399
52-Week Range:
$0.135
$4.12
Molecular Templates Inc Stock (MTEM) Company Profile
Name
Molecular Templates Inc
Sector
Industry
Phone
512 896 1555
Address
9301 AMBERGLEN BLVD, AUSTIN, TX
Compare MTEM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTEM
Molecular Templates Inc
|
0.16 | 1.05M | 23.48M | -15.63M | -23.92M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Molecular Templates Inc Stock (MTEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-21 | Initiated | BofA Securities | Buy |
| Feb-01-21 | Initiated | UBS | Neutral |
| Sep-08-20 | Initiated | Jefferies | Buy |
| Mar-25-20 | Initiated | Stifel | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Apr-29-19 | Initiated | UBS | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Oct-08-18 | Initiated | Laidlaw | Buy |
View All
Molecular Templates Inc Stock (MTEM) Latest News
MTEM stock touches 52-week low at $0.15 amid sharp annual decline - Investing.com
Molecular Templates faces Nasdaq delisting By Investing.com - Investing.com Canada
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.18% - Investing.com
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Why Molecular Templates (MTEM) Stock Is Down 60% - Benzinga
MTEM stock touches 52-week low at $0.15 amid sharp annual decline By Investing.com - Investing.com South Africa
Molecular Templates faces Nasdaq delisting - Investing.com
Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules - The Manila Times
Molecular Templates Faces Nasdaq Delisting After Multiple Compliance Failures - StockTitan
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Inkl
Dyne Therapeutics (DYN) Stock Drops Amidst Biotech Sector Moveme - GuruFocus.com
Artelo Biosciences (ARTL) Stock Surges 5% Amid Strong Buy Ratings - GuruFocus.com
Stock market news: Molecular Templates increased by 60.83% while Algorhythm Holdings dipped by 47.40% during mid day trading - Business Upturn
Molecular Templates Announces Key Leadership Transition - TipRanks
Molecular Templates, Inc. Announces Executive Changes - Marketscreener.com
Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements - Marketscreener.com
Molecular Templates Faces Dual Nasdaq Compliance Warnings Over Filing, Stock Price - StockTitan
Stock Region Signal Report - substack.com
Molecular Templates faces delisting, seeks stockholder approval for dissolution - Investing.com India
Molecular Templates faces delisting, seeks stockholder approval for dissolution By Investing.com - Investing.com Australia
Compugen (CGEN) Stock Dips Amidst Biotech Sector Movements - GuruFocus.com
Capricor Therapeutics (CAPR) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
United States shares lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
BB Biotech AG's Strategic Acquisition in Molecular Templates Inc - GuruFocus.com
Alphabet Cl A (GOOGL-Q) QuotePress Release - The Globe and Mail
Bb Biotech sells $845,833 in Molecular Templates shares - Investing.com India
Bb Biotech sells $845,833 in Molecular Templates shares By Investing.com - Investing.com UK
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register
Analysts Predict Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) To Loss -577.97% From Current Levels. - Stocks Register
Molecular Templates Inc (NASDAQ: MTEM) Drops -23.41 Percent In Recent Session, Why Are You Interested? - Stocks Register
Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
HALO Stock Dips 5.77% Amid Biotech Sector Changes - GuruFocus.com
Agenus (AGEN) Stock Dips Amid Financial Performance and Industry Trends - GuruFocus.com
U.S. STOCKS Talen Energy, Biogen, Ovintiv - XM
U.S. Stock market: Molecular Templates surges by 155.81% while Sow Good declines by 53.39% during mid day trading - Business Upturn
Austin InnoProper Good heads to the big box | Austin startups on the Deloitte Fast 500 - The Business Journals
Clairity Appoints Jeffrey R. Luber CEO as Firm Prepares for Global Expansion - cnhinews.com
Clairity Appoints Jeffrey R. Luber as CEO - citybiz
Molecular Templates Inc Stock (MTEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Molecular Templates Inc Stock (MTEM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BIOTECH TARGET N V | 10% Owner |
Apr 02 '24 |
Buy |
2.35 |
250,000 |
587,500 |
1,279,820 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):